Vaccinex’s Post

📋 A regimen of PD-1 inhibitors and chemoradiotherapy may benefit esophageal tumor vascular normalization, alleviate hypoxia, enhance radiosensitivity, and improve local control for patients. Learn how this treatment can aid patients with #esophagealcancer:

📋 A regimen of PD-1 inhibitors and chemoradiotherapy may benefit esophageal tumor vascular normalization, alleviate hypoxia, boost radiosensitivity, and improve local control for patients. Learn how the treatment can aid patients with #esophagealcancer:

The Poor Richard’s Almanac proverb, “time lost is never found again,” applies to head and neck cancer since treatment delays or discontinuations from severe oral mucositis are a risk factor for recurrence and shortened survival times. The Phase 2 clinical trial, KEVLARx will combine RRx-001 (nibrozetone) with cisplatin and radiotherapy to prevent or mitigate the toxicity of severe oral mucositis. Read more here: https://bit.ly/4dd8nlv.

In a multicenter, randomized Phase 3 trial, capecitabine and XELOX were found to have similar efficacy to PF in definitive concurrent chemoradiotherapy (DCRT) for inoperable locally advanced esophageal squamous cell carcinoma (ESCC). Notably, capecitabine demonstrated a lower incidence of severe adverse events compared to PF, suggesting it as a more tolerable alternative. Additionally, consolidation chemotherapy provided a significant survival benefit over DCRT alone. These findings may influence future treatment protocols for ESCC, emphasizing the potential for better patient outcomes with capecitabine-based regimens. #EsophagealCancer #Chemoradiotherapy #OncologyResearch #CancerTreatment #ClinicalTrials

NRG-LU008 is a #clinical trial for patients with locally advanced, inoperable, node-positive non-small cell #lungcancer (NSCLC) testing the + SBRT delivered to the primary lung tumor followed by RT & concurrent platinum-based chemotherapy. Learn more: https://ow.ly/GcAV50Q77T5

Immuneering! IMRX! Read below! Novel drug discovery!

Summary: The article discusses the promising efficacy of a chemotherapy-free regimen combining eftilagimod alpha with pembrolizumab in patients with advanced PD-L1-negative head and neck squamous cell carcinoma

The #KIT ligand #KITLG promotes portal vein tumor #thrombosis by up-regulating COL4A1 through STAT3-SMAD2 signaling in hepatocellular carcinoma https://lnkd.in/egPH4d6Y

Gain valuable insights into how collaboration among different healthcare professionals can lead to early detection and better outcomes for patients with advanced cases of basal cell carcinoma (BCC) and advanced cutaneous squamous cell carcinoma (CSCC). Register here: https://okt.to/jbM5hq

📋 PD-1 inhibitors with chemoradiotherapy may benefit esophageal tumor vascular normalization, alleviate hypoxia, boost radiosensitivity, and improve local control for patients. 👉 Learn how the treatment can aid patients with #esophagealcancer: